Published in

Elsevier, Annals of Oncology, 5(26), p. 1040, 2015

DOI: 10.1093/annonc/mdv141

Elsevier, Annals of Oncology, 2(26), p. 340-347, 2015

DOI: 10.1093/annonc/mdu539

Links

Tools

Export citation

Search in Google Scholar

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): A pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial

Journal article published in 2014 by M. Hebbar, B. Chibaudel, T. André, L. Mineur, D. Smith, C. Louvet, J. L. Dutel, M. Ychou, J. L. Legoux, M. Mabro, R. Faroux, D. Auby, D. Brusquant, A. Khalil, S. Truant ORCID and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The sequential FOLFOX7-FOLFIRI combination is not superior to FOLFOX4 in colorectal cancer patients with resectable metastases. Patients with synchronous metastases preferably received perioperative chemotherapy, while patients with metachronous metastases were given postoperative chemotherapy in preference. We observed the highest long-term survival rates ever reported in this setting. © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.